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192 Clinical practice in Oslo University Hospital on diagnosis and
management of distal intestinal obstructive syndrome
J. Dypvik1,2, O.-T. Storrøsten1. 1Norwegian Resource Centre for Cystic Fibrosis,
Oslo University Hospital Ulleva˚l, Oslo, Norway; 2Akershus University Hospital
and Institute of Clinical Medicine, University of Oslo, Department of Obstetrics
and Gynecology, Oslo, Norway
Objectives: Investigation of the diagnostic process and treatment of Distal Intestinal
Obstructive Syndrome (DIOS) in Norwegian Cystic Fibrosis patients in comparison
with ECFS guidelines.
Methods: Retrospective review of electronic patient ﬁles from 50 CF patients.
19 of these patients experienced at least one suspected episode of DIOS within
the previous 5 years. The 19 patient records were systematically reviewed for
information about symptoms of DIOS, clinical work-up and treatment.
Results: The included patients had an equal gender distribution and were born
in 1977–2007. 18 patients had a serious genetic mutation. 17 had pancreatic
insufﬁciency. 18 patients reported two or more symptoms of DIOS. 7 patients
were examined with an abdominal x-ray. 3 patients got a diatrizoinic acid lavage
as a part of the diagnostic and treatment regimen. 8 patients were hospitalized
and received 7 different treatment regimens. 18 patients got N-acetylcystein as
prophylactic treatment after an episode of DIOS. None of the patients was treated
with laxatives containing polyethylene glycol.
Conclusion: Signiﬁcant divergence from ECFS guidelines (2011) was identiﬁed on
the hospitals performance on diagnostic work up and treatment for DIOS. Our
opinion was that the attending physicians and the patients would beneﬁt from
speciﬁc guidelines in how they approach CF patients with possible DIOS.
Clinical impact: Guidelines on diagnosis and management of DIOS, based mainly
on the ECFS guidelines, were constructed and implemented in April 2013.
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Calprotectin is a protein which, due to its antibacterial and anti-proliferative activity,
plays a regulatory role in the inﬂammatory reactions.
The aim of this study was to evaluate the concentration of calprotectin in the stool
of patients with cystic ﬁbrosis.
Patients and Methods: The study included 41 patients, at the ages of 7 weeks to
18 years (mean age of 4 years). The study group was divided into two subgroups:
subgroup 1 (23/41, 56.1%) included patients with cystic ﬁbrosis diagnosed during
screening tests, and subgroup 2, which consisted of 18 children (18/41, 43.9%)
not included in the screening test, in whom CF was diagnosed during diagnostic
examination. In all patients, the concentration of calprotectin in stool samples was
measured by PhiCal ELISA test. The analysis included clinical manifestation and
laboratory test results. The results were statistically analyzed.
Results: Elevated levels of calprotectin in faeces were observed in 4/41 (9.7%)
patients with cystic ﬁbrosis and delta F508/delta F508 mutation, mostly in older
children − aged over 10 years old. There was no correlation between the concentra-
tion of calprotectin and clinical symptoms, age, elevated markers of inﬂammation
in the blood serum, serum protein and transaminases levels as well as the values
of acid steatocrit in the stool.
Summary: Determination of calprotectin concentration in the stool of children
diagnosed with cystic ﬁbrosis does not correlate with the severity of changes in
the gastrointestinal tract (pancreas, liver). Therefore, continuation of the previous
studies seems necessary.
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Objectives: Gastro-oesophageal reﬂux (GER) frequency in CF is between
30% and 80% and contributes to the respiratory decline; however the 2011 French
registry reported a rate of 17%. This survey was designed to assess the variation
in the investigations and treatment of GER among CF centres (CFC).
Methods: Questionnaires were sent to all CFC (n = 49). Collected information
included diagnosis and therapeutic modalities with a single reply per centre.
Results: 29 CFC replied (60%), representing 73% of the national cohort
(55% <18 y). No CFC carried out routine diagnostic evaluation; only 38 and 55%
evaluated GER before enteral feeding (EF) and lung transplant (LT) respectively.
All CFC mentioned pH probe or multichannel intraluminal impedance with pH
when available (31%) as ﬁrst line diagnosis test; proton pump inhibitors (PPI)
were not discontinued before pH monitoring in up to 29% of CFC and in case
of discontinuation the delay was <7 d in 68%. Second line test for diagnosis were
baryium swallow (31%, mainly in children) and upper endoscopy (41%, mainly in
adults). Treatment relied on PPI for all CFC and on additional use of prokinetic
agents or antacids both in 20%. Efﬁcacy of treatment was nearly never performed.
Indication for antireﬂux surgery was only discussed before starting EF (30%) and
LT waiting list (30%). Only 5 CFC (17%, only paediatric) had a gastroenterologist
involved in the CF team.
Conclusions: Our survey showed
1. wide variations in GER assessment, accounting for the underestimated fre-
quency;
2. the difﬁculty in involving a GI physician with an interest in CF;
3. the need for national or European guidance for GER management in the
context of CF.
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Objectives: With survival increasing in CF, CF related diabetes (CFRD) is be-
coming more common. In some children a pre-diabetic phase of abnormal glucose
tolerance occurs before CFRD is reached. The aim of this study was to assess
the utility of CGMS in the management of impaired and indeterminant glucose
tolerance in children with CF.
Methods: An OGTT was performed on all CF patients aged 10 years and over and
in CF patients aged less than 10 years with poor clinical status. Patients with a 1
hour blood glucose >11.1mmol/L but a 2 hour glucose <7.8mmol/L were deﬁned
as having indeterminant glucose tolerance. Impaired glucose tolerance was deﬁned
as a 2 hour blood glucose on OGTT of between 7.8–11.1mmol/L. All children with
impaired or indeterminant glucose tolerance had CGMS performed.
Results: 10 children had impaired glucose tolerance and 7 had an indeterminate
glucose tolerance. Of the 10 patients with impaired glucose tolerance, 3 had normal
CGMS. In 7, the CGMS showed high blood glucose peaks after meals and dietary
advice was given. 3 of these patients had a repeat CGMS 6 to 9 months later. In 2
patients, the CGMS showed features consistent with CFRD and were commenced
on insulin. Of the 7 patients with indeterminate glucose tolerance, only one CGMS
was abnormal and dietary advice was given. The CGMS was repeated, with ﬁndings
consistent with CFRD and insulin was commenced.
Conclusion: This study has shown the utility of CGMS to enhance the treatment
of early glucose dysregulation in CF children. CGMS can help direct nutritional
advice, as well as optimise management in terms of commencement of insulin
therapy.
